Related Experiment Video
Updated: Aug 28, 2026

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
Published on: May 12, 2019
Advances in the Intestinal Toxicity of Microcystin-LR
Yichen Li1, Jiaqian Gong1, Rui Liu1
1School of Nursing and Health, Nanfang College Guangzhou, Guangzhou, Guangdong, China.
Abstract:
Microcystin-LR (MC-LR), the most prevalent and toxic microcystin congener, is a persistent cyanotoxin that reaches humans mainly through contaminated water and food. Because the intestine is the first tissue exposed after ingestion, it is both a portal of systemic uptake and a direct toxicological target. This review integrates evidence on intestinal distribution and absorption, exposure-dependent toxic phenotypes, and molecular mechanisms. Acute or high-dose exposure predominantly causes villus erosion, epithelial apoptosis, cytoskeletal collapse, and rapid barrier failure, whereas repeated exposure at low or environmentally relevant doses produces low-grade inflammation, fibrosis, microbiota and metabolite dysregulation, and increased susceptibility to colitis and colorectal tumor progression. Mechanistically, organic anion-transporting polypeptide-mediated uptake and inhibition of protein phosphatase 2A (PP2A) act as upstream events that promote protein hyperphosphorylation and interconnected oxidative stress, DNA damage, tight-junction disassembly, inflammatory signaling, and dysregulated proliferation, apoptosis, migration, and invasion. Recent multiomics and fecal microbiota transplantation studies further support a bidirectional microbiota-barrier-immune axis in local and systemic effects. Quantitative interpretation nevertheless remains limited by heterogeneous dose metrics, short experiments, nonphysiological exposure routes, and scarce human longitudinal data. Future studies should prioritize environmentally realistic chronic and mixture exposures, human intestinal organoids and organ-on-chip systems, causal PP2A pathway perturbation, longitudinal biomonitoring, and harmonized benchmark-dose analyses.
More Related Videos
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
12:58A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Related Concept Videos
Microbial Corrosion
Drugs for Treatment of Constipation-Predominant IBS